Optimi Health Completes First 2026 Production of MDMA and Psilocybin Capsules

Executive Summary

• Optimi Health Corp. completed a production cycle of 1,000 MDMA (60 mg) and 1,000 psilocybin (5 mg) capsules for export to Australia under the Authorised Prescriber Scheme.
• The batch was packaged, labelled, released and certified GMP‑compliant with full Certificates of Analysis and Australian import permits secured.
• Completion positions the company to expand access to psychedelic therapies for PTSD and treatment‑resistant depression across Australia in 2026.

Key Details

• Batch Size: 1,000 MDMA capsules (60 mg each) + 1,000 psilocybin capsules (5 mg each).
• Regulatory Compliance: Produced under Health Canada Drug Establishment Licence; GMP‑compliant; batch release approved by Health Canada.
• Export Authorization: Australian import permits obtained; capsules cleared for supply under Australia’s Authorised Prescriber Scheme.
• Quality Assurance: Certificates of Analysis confirm conformance with all applicable quality specifications.
• Market Impact: Enables continued and expanded supply of MDMA and psilocybin therapies to Australian clinics treating PTSD and TRD.
• CEO Quote: “This production run has been released and approved for import, allowing Optimi to continue supplying MDMA and psilocybin into Australia's regulated healthcare system… positions us to expand access across the country for patients suffering from PTSD and TRD.” – Dane Stevens, CEO

Notable Quotes

"Completing this first production cycle of 2026 positions us to expand access across the country for patients suffering from PTSD and TRD." – Dane Stevens, Chief Executive Officer

All boilerplate, forward‑looking statements, and contact information have been omitted for brevity.